It is critical that applicants follow the instructions in the Application Guide (SF424 (R&R) Application Guide, eRA Commons Administrative Supplement User Guide or PHS 398 Application Guide, as appropriate) except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information

The National Cancer Institute (NCI) is committed to reducing cancer health disparities that affect all health disparity and underserved populations in the United States and to supporting research education, training, and capacity building within and near these communities. The NCI established the Center to Reduce Cancer Health Disparities (CRCHD) to strengthen cancer research by: addressing cancer health disparities (CHD); advising on strategic priorities, program direction, and scientific policy to strengthen cancer disparities research and training; and leading NCI's efforts to enhance scientific workforce diversity through identifying and training students and investigators from underrepresented backgrounds.

As part of its mission to strengthen disparities research and training, the NCI proposes to award 2-year administrative supplements to existing P30 Cancer Center Support Grants (CCSGs) at NCI-designated Cancer Centers (CCs) through CRCHD’s Geographic Management of Cancer Health Disparities Program (GMaP). This funding opportunity announcement (FOA) will support seven region-based hubs or networks. These hubs will: facilitate underrepresented investigator/trainee recruitment and career/professional development; provide enhanced capacity in the areas of disparities research; and promote CHD research infrastructure development and evaluation. In addition, the GMaP network will create regional linkages and connections with networks of local contacts in CCs, institutions serving underserved health disparity populations and underrepresented students (ISUPS), and other organizations and agencies on topics of and related to CHD and improving diversity in the biomedical workforce. These GMaP supplements will leverage the significant resources and infrastructure available at the CCs, and within CRCHD flagship programs, including: Continuing Umbrella of Research Experiences (CURE), Partnerships to Advance Cancer Health Equity (PACHE), and the National Outreach Network (NON).

The goals of the GMaP initiative are to: 1) support and enhance the science of CHD; 2) promote the development of the next generation of competitive, underrepresented cancer and CHD investigators; and 3) enhance access to cancer information and research among underserved communities. To achieve these goals, the program will have the following core functions:

• Support/Enhance Cancer and CHD Research Infrastructure. GMaP aims to identify and increase awareness of regional research assets to enhance cancer and CHD research and its translational applicability. Additionally, it seeks to improve the competitiveness of funding applications across a broad range of basic, clinical, translational, and behavioral/population-based topics; increase biospecimen collection and biobanking, particularly among racial/ethnic minorities; and enhance clinical research. GMaP will create linkages within regions by seeking collaborations with Cancer Centers; community-based organizations; NON; PACHE; other community health educators (CHEs); researchers; institutions; and other agencies conducting or supporting cancer and CHD research.
• Enhance Workforce Diversity. GMaP aims to identify trainees and investigators to infuse the CURE pipeline with competitive trainees and increase the representation of underrepresented minorities in the cancer and CHD research workforce. GMaP will create linkages within regions via collaborations with Cancer Centers; PACHE; ISUPS, including Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions (HSIs), tribal colleges and other academic institutions serving underrepresented populations; academic institutions with Kirschstein-National Research Service Awards (T32); and other agencies engaged in training underrepresented individuals.

It is expected that each GMaP region will facilitate/promote close affiliation with NON and PACHE CHEs. This close affiliation will further strengthen the ability of the NCI and NCI-designated CCs to reach underserved communities with cancer information through region-based community education/ outreach activities as aligned with NCI research priorities, including educational efforts to promote participation in cancer clinical trials and biospecimen donation, especially from racial/ethnic minorities.

It is also expected that each GMaP region will facilitate a close affiliation with the PACHE and CURE diversity training efforts. This enhanced affiliation with CRCHD flagship programs will further facilitate attainment of National Institutes of Health's (NIH s) and NCI’s goal of increased diversity of the biomedical research workforce by supporting opportunities for sustained and integrated research training and education of the next generation of talented scientists from underrepresented backgrounds. It is expected that consistent and recurring communication will be enacted within the region regarding cancer research and diversity training funding opportunities and resources, and trainee career development and networking opportunities to leverage the CURE program.

GMaP will continue to operate through its existing seven-region structure (see https://www.cancer.gov/about-nci/organization/crchd/inp/gmap#hubs). Each region must have an infrastructure in place for connecting CRCHD and the cancer and CHD research, training, and outreach/education enterprise with underrepresented students/trainees and investigators and underserved communities. These connections will be accomplished through implementation of a structured, ongoing communication/information dissemination plan that provides linkages between the CRCHD program directors, the RCD at each regional GMaP hub, the NON and PACHE CHEs located within each region, leaders of the PACHE research education cores located in each region, and regional stakeholders (e.g., trainees, researchers, CCs, ISUPS, FQHCs and community hospitals, CBOs). Through routine dissemination of information/resources and mentoring/networking opportunities, GMaP will continue to serve as a central resource for information about NCI and CRCHD programs or initiatives for trainees and researchers, CCs, ISUPS and other academic institutions, and community organizations; regional/state stakeholders for research, training, and outreach resources; and existing and potential partners.

Upon the completion of the work supported by an administrative supplement, each GMaP hub should be demonstrating its capacity to serve as a primary source of information related to multiple types of research resources as well as a liaison between the key stakeholders discussed above in a sustainable manner.

Background

The NIH and NCI are vested in working toward eliminating health disparities while supporting an understanding of elements that contribute to health and well-being. Specifically, the mission of NIH is to acquire new knowledge that will lead to better health by understanding the processes underlying health and disease that in turn will help prevent, detect, diagnose, and treat disease and disability. NIH's ability to further its mission and help ensure that the nation remains a global leader in scientific discovery and innovation is dependent upon providing resources and infrastructure to support the development of a pool of highly talented scientists from diverse backgrounds.

The Geographic Management of Cancer Health Disparities Program (GMaP) employs a comprehensive strategy for building region-based hubs or networks. Each GMaP hub is expected to reflect, through its participating investigators and their research efforts, the breadth and depth of science related to cancer health disparities (CHD) in the areas of basic, clinical, translational, and community-based research.

Eligibility Requirements

This funding opportunity utilizes NCI-designated CCs, which are supported by P30 grants. Principal Investigators (PIs) of these grants may apply for administrative supplements provided all the following conditions are met:

• The PI designated for the administrative supplement request must also be the current PI of the active parent grant;
• The focus of the administrative supplement must align with the research priorities of the original ( parent ) CC grant;
• The PI may designate a Project Director (PD) to oversee the supplement. A PD should be a mid-to-senior level scientist with appropriate institutional investment and support and be willing to work collaboratively, locally and regionally (with investigators associated with NON and PACHE);
• Co-PIs are not allowed.

Scope of Activities

The current supplement opportunity provides support for one full-time equivalent (FTE) GMaP RCD to be located at a GMaP hub housed at an NCI-designated CC. The applicant is required to submit an administrative supplement request that addresses the goals of the GMaP initiative and utilizes a mature infrastructure to connect NCI priorities, CRCHD, CHD research, training, and outreach/education with underrepresented students/trainees and investigators and underserved communities. The focus of the RCD will be to implement strategies to: 1) identify and promote the career development of persons underrepresented in the cancer and CHD research workforce; 2) identify and promote the use of biospecimen resources including promotion of biospecimen donation among racial/ethnic minorities; and 3) consistently disseminate information related to NCI priorities, diversity workforce development training, including career development opportunities, biospecimen resources, and cancer and CHD research. Additionally, regional GMaP activities should demonstrate alignment with local, regional, and NCI research priorities, as well as ongoing interaction with and support for activities and initiatives associated with the CURE, NON, and PACHE programs.

Each GMaP hub will serve as a resource center that addresses these core functions by implementing region-specific priority programmatic activities related to research training; local, State, and regional engagement; special initiatives and partnerships; and CRCHD support.

Career Development

The purpose of the Career Development initiative is to identify and support connection of underrepresented students, trainees and early stage investigators with research training and other career development opportunities, as well as with cancer and CHD investigators for mentorship. To achieve these objectives, RDCs will engage in the following activities:

• Identify and document current and potential CURE scholars at all levels of career development including undergraduate, graduate, post-doctoral and Early Stage Investigators (ESIs). This information should be retained in a database and routinely updated.
• Identify and document current NCI grantees who hold R-type funding awards (e.g., R01, R21, P01, U01), area(s) of research, and availability and willingness to serve as a Mentor. This information should be retained in a database and routinely updated.
• Identify CURE scholars and NCI grantees who are currently engaged (or have recently engaged) in CHD research. For CURE scholars, also include documentation of those with an interest in CHD research but who are not currently engaged in CHD research.
• Develop linkages with strategic partners (e.g., ISUPS with graduate programs, T32 investigators) and serve as a liaison for current/potential CURE students, trainees, and early stage investigators. The RCD will be expected to maintain and routinely update a database of contact information for these strategic partners.
• Identify career development resources within the region and maintain and routinely update a database that houses this information.
• Routinely communicate pertinent information to potential and current CURE scholars regarding career development opportunities including but not limited to: training opportunities, technical assistance workshops, employment opportunities, regional and national scientific meetings and seminars, webinars. It is expected that this information will be communicated through a variety of channels to enhance the effectiveness of the communications.
• Maintain close communication and coordination with CRCHD to enhance the impact of implemented strategies and work collaboratively with stakeholders to support tracking of CURE scholars career progressions using local and regional networks, and routinely report efforts and results to CRCHD.

Biospecimen/Biobanking

The purpose of the Biospecimen/Biobanking initiative is to promote both the donation of biospecimens among racial/ethnic minorities and greater utilization of biobanking resources to enhance cancer and CHD research. To achieve these objectives, RCDs will engage in the following activities:

• Conduct an environmental scan of biospecimen/biobanking resources in the region. RCDs are expected to develop a database that minimally documents: location of resource (institution), point of contact, and contact information; specimen type; cancer type (or normal specimen); tissue/organ site; number of samples; associated information (e.g., race/ethnicity, gender, age, SES).
• Update database on a regular basis including addition of new resources as applicable.
• Communicate/highlight resources to the research community through multiple channels.
• Provide support to CURE scholars in development of proposals for use of available biospecimens. This support could include technical assistance as well as monetary support as necessary.
• Coordinate with NON and PACHE CHEs regarding available tools for promotion of biospecimen donation among racial/ethnic minorities; maintain a repository of evidence-based resources that are in alignment with NCI-approved messaging.
• Develop connections and coordinate activities with other NCI programs and initiatives like NCI Community Oncology Research Program (NCORP) and All of Us Research Program, to further enhance NCI’s ability to reach a broader sample of persons throughout the United States.
• Communicate funding opportunities to the research community, including CURE scholars, regarding CHD research as it relates to biospecimens.

Consistent with the above activities, the RCD will attend scientific meetings and, in alignment with NCI priorities, provide information about coordination on addressing emergent cancer and CHD issues.

Submission

Cancer centers interested in applying for this supplement opportunity are encouraged to contact the CRCHD program staff members indicated below.

Requests for these administrative supplements must be submitted to the NCI Center to Reduce Cancer Health Disparities (CRCHD) (see address below). Applications must be prepared using the current PHS 398 grant application forms (available at http://grants1.nih.gov/grants/funding/phs398/phs398.html).

Font size restrictions apply as designated within the PHS 398 instructions. Note that the NIH Center for Scientific Review (CSR) is NOT involved in receipt and referral of these requests.

See Section VIII. Other Information for award authorities and regulations.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

All organizations administering an eligible parent award may apply for a supplement under this announcement.

Higher Education Institutions

• Public/State Controlled Institutions of Higher Education
• Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

• Hispanic-serving Institutions
• Historically Black Colleges and Universities (HBCUs)
• Tribally Controlled Colleges and Universities (TCCUs)
• Alaska Native and Native Hawaiian Serving Institutions
• Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

• Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
• Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

• Small Businesses
• For-Profit Organizations (Other than Small Businesses)

Governments

• State Governments
• County Governments
• City or Township Governments
• Special District Governments
• Indian/Native American Tribal Governments (Federally Recognized)
• Indian/Native American Tribal Governments (Other than Federally Recognized)
• Eligible Agencies of the Federal Government
• U.S. Territory or Possession

Other

• Independent School Districts
• Public Housing Authorities/Indian Housing Authorities
• Native American Tribal Organizations (other than Federally recognized tribal governments)
• Faith-based or Community-based Organizations
• Regional Organizations

This announcement is for supplements to existing projects. To be eligible, the parent award must be active and the research proposed in the supplement must be accomplished within the competitive segment. The proposed supplement must be to provide for an increase in costs due to unforeseen circumstances. All additional costs must be within the scope of the peer reviewed and approved project.

IMPORTANT: The research proposed by the NIH grantee in the supplement application must be within the original scope of the NIH-supported grant project.

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. Since administrative supplements are made against active grants and cooperative agreements, many of these registrations may already be in place. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

• Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
• System for Award Management (SAM) (formerly CCR) Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
• NATO Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
• eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
• Grants.gov Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration. Grants.gov registration is only required if you plan to submit using the 'Electronic Application Submission through Grants.gov' option.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Individual(s) must hold an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Individuals are encouraged to work with their organizations to develop applications for support.

For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award. Do not use this administrative supplement application to add, delete, or change the PDs/PIs listed on the parent award. Visit the Multiple Program Director/Principal Investigator Policy in the SF424 (R&R) Application Guide for more information.

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

An eligible institution may only submit one (1) application.

Although the financial plans of NCI provide support for this program, administrative supplement awards pursuant to this initiative are contingent upon the availability of funds and the receipt of a sufficient number of competitively reviewed meritorious requests.

All requests must include a detailed budget and budget justification using the standard PHS 398 form budget pages.

Applicants must prepare applications using current forms in accordance with the Application Guide.

Buttons to access the online ASSIST system or to download application forms are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

All forms must be completed for the supplemental activities only and must not reflect funding or activities for the previously awarded parent award.

It is critical that applicants follow the instructions for their submission option (SF424 (R&R) Application Guide, eRA Commons Administrative Supplement User Guide or PHS 398 Application Guide, as appropriate) including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to documented requirements is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.

All page limitations applicable to the parent award as described in the Application Guide and the Table of Page Limits must be followed, with the following exceptions or additional requirements:

Administrative supplement requests for most single-project activity codes can be submitted using either paper or electronic submission processes. Administrative supplement requests for multi-project activity codes must be submitted using the paper submission process. See Activity Code section in Part 1 to determine if electronic submission is an option for your activity code.

Applicants submitting paper applications must use the PHS 398 Application Forms and the PHS 398 Application Guide (available at http://grants1.nih.gov/grants/funding/phs398/phs398.html). Font size restrictions apply as designated within the PHS 398 instructions. Note that the NIH Center for Scientific Review (CSR) is NOT involved in receipt and referral of these requests. All requests must include the following:

• Cover Letter Citing this Administrative Supplement by title, and the following information:
  
  
• PI name (must be the same as the parent grant PI or designee);
• Parent grant number and title;
• Request up to two (2) years of support and provide the amount of the requested supplement (include direct and indirect costs);
• Name and title of the institutional official; Phone, e-mail, and address information for both the PI and institutional official; and 
• The cover letter should be signed by the PI and an appropriate institutional official documenting specific institutional commitment for this award, including office space for the RCD as needed, a plan to integrate the RCD in the CC, and for the long-term sustainability of the RCD.

PHS 398 Form Page 1 (Face page) MS Word PDF

• The title of the project (Box 1) should be the title of the parent grant.
• The title of the Notice Administrative Supplements to Enhance NCI-supported Workforce Diversity and Biospecimen Collection/Biobanking through Geographical Management of Cancer Health Disparities Program (GMaP) should be cited in Box 2, and the yes box should be checked.
• The PI of the parent grant must be the PI of the supplement request.
• The remaining items on the face page should be filled out in accordance with the PHS 398 application instructions.

PHS 398 Form Page 2 (Project Summary) MS Word PDF

• Provide the Summary of the proposed supplement (NOT the summary for the parent grant). The summary should identify the proposed key strategies to achieve the objectives of the administrative supplement and define metrics and benchmarks to be used to evaluate the efficacy/impact of the strategies used.

Prepare applications using the SF424 (R&R) forms associated with the chosen package. The NCI intends to commit approximately $1.25M per year to fund seven (7) GMaP administrative supplements to P30 awards in response to this announcement.

Although the financial plans of NCI provide support for this program, administrative supplement awards pursuant to this initiative are contingent upon the availability of funds and the receipt of a sufficient number of competitively reviewed meritorious requests.

All requests must include a detailed budget and budget justification using the standard PHS 398 form budget pages.

Applicants may request up to $175K in total costs (direct and all F&A costs) per year for up to 2 years.

Continuation of supplement funding beyond the initial year is contingent upon scientific progress and availability of funds.

All requests must include a detailed budget and justification using the standard PHS 398 form budget pages.

Allowable costs include:

Salary support plus fringe benefits for the RCD, commensurate with the percent level of effort. One RCD per Region is allowed.

Participation in up to two face-to-face meetings (e.g., annual GMaP/NON program meeting, regional meeting, or conference for presentation purposes), for which limited travel costs need to be included in the submitted budget.

Salary, research costs, and other activities of the PIs are not allowable under this effort.

A brief Proposal Describing the Supplemental Activities: This section should contain sufficient detail to allow assessment of the scientific merit of the proposed plans and activities, and the appropriateness of the request for supplemental funds.

Introduction (limit half page)

Specific Aims (limit half page)

RCD Description (limit half page)

RCD-facilitated Career Development and Biospecimen/Biobanking activities (limit to 3 pages)

Introduction: Describe how the proposed supplemental activities relate to the parent grant.

Specific Aims: Include a brief statement of expected impact and relevance of the RCD and RCD-facilitated career development and biospecimen/biobanking promotion activities on the career development of CURE scholars and the use of biospecimen resources.

RCD Description: Describe the expertise, qualifications, and relevant prior experiences, and accomplishments of the proposed RCD. This [what?] should include the roles and responsibilities of the RCD and evidence of the RCDs integration into the CC infrastructure and focus. These roles and responsibilities should be clearly associated with the application’s specific aims and anticipated outcomes.

RCD-Facilitated Career Development and Biospecimen/Biobanking Promotion

Describe the proposed RCD-facilitated career development and biospecimen/biobanking promotion program and explain how it relates to the priority areas and objectives defined in this administrative supplement program.

Address the following specific aspects:

• Identify and describe the elements of the proposed organizational structure, including roles and responsibilities of the hub’s team members and partners, as well as the RCD’s integration and interactions. Of special interest is the interaction and regularity with which the RCD will engage with CC leadership in the region.
• Describe a plan for strengthening the regional hub’s ability to increase capacity for identifying, leveraging, and/or disseminating resources, knowledge, and expertise related to increasing the competitiveness of applicants for CURE and other funding opportunities, as well as engaging with organizations at the local, State, and regional levels. This plan will ideally identify and include descriptions of previous partnership engagement and planned new partnerships in the region, such as with other CCs; PACHE sites in the region; NCI-supported research, workforce diversity, and minority health/health disparity-focused education/outreach programs, and other community and/or non-profit organizations; academic institutions, including those serving underrepresented researchers, trainees/students; and professional societies and scientific organizations, as well as regional NON and PACHE CHEs. Letters of support and lists of previous/proposed partners are strongly encouraged.
• Describe a plan to identify and promote increased biospecimen donation among racial/ethnic minorities in the region. This plan should include how the RCD intends to coordinate and interact with NON and PACHE CHEs and other NCI programs like NCORP to support these activities and achieve the stated objectives related to biospecimen donation. In addition, there should be a description of how the RCD will conduct an environmental scan of biospecimen/biobanking resources in the region and how this information will be used to promote use of these resources among cancer and CHD researchers.
• Describe a plan to identify, track, and assess the activities of the GMaP hub, including short-term and mid-term outcomes, and projected impact of the GMaP activities on the Cancer Center and workforce diversity efforts, regional disparities research, and minority health/health disparity populations. It is expected that GMaP supported activities will be documented via data elements or indicators associated with proposed outcomes.
• Provide a detailed communication plan related to identification of potential CURE scholars, promotion of career development of CURE scholars, and identification and dissemination of biospecimen/biobanking resources in the region. This plan should include target audiences, media channels including new media, and frequency of communications.
• Explain how the proposed GMaP activities can be reasonably and feasibly accomplished during the supplement period, including a timeline with milestones for the establishment and operation of the GMaP regional hub?
• Biographical Sketch for RCD: Biosketch must adhere to the PHS 398 format and requirements (MS Word, PDF). If a RCD candidate has not yet been identified, provide a brief description of the qualifications/experience sought, and timetable for recruitment and hiring.
• R&R Cover form: Select Revision in the Type of Application field.
• Research Plan form: The Research Strategy section should be completed and must include a summary or abstract of the funded parent award or project. Other sections should also be included if they are being changed by the proposed supplement activities.
• Project/Performance Site Location form: Include the primary site where the proposed supplement activities will be performed. If a portion of the proposed supplement activities will be performed at any other site(s), identify the locations in the fields provided.
• Sr/Key Personnel form: List the PD/PI as the first person (regardless of their role on the supplement activities). List any other Senior/Key Personnel who are being added through this supplement, or for whom additional funds are being requested through this supplement; include a biographical sketch for each.
• Budget forms (e.g., R&R Budget, PHS 398 Training Budget): Only include funds requested for the additional supplement activities.
• R&R Other Project Information form: If applicable, attach PDF documents in the Other Attachments field indicating that the proposed research experience was approved by the Institutional Animal Care and Use Committee (IACUC) or human subjects Institutional Review Board (IRB) at the grantee institution. Name the documents IACUC Documentation.pdf and/or IRB Documentation.pdf . Adherence to the NIH policy for including women and minorities in clinical studies must also be ensured, if additional human subjects involvement is planned for the supplement.

Instructions for Paper-based Submissions using the PHS 398 Application Forms

Applications must be prepared using the PHS 398 research grant application forms and instructions for preparing a research grant application, with the following additional guidance:

• Checklist: Select Revision in the Type of Application field.
• Face Page (Form Page 1): On the face page of the application form, note that your application is in response to a specific program announcement, and enter the title and number of this announcement.
• Research Plan: The Research Strategy section should be completed and must include a summary or abstract of the funded parent award or project. Other sections should also be included if they are being changed by the proposed supplement activities.
• Project/Performance Sites section (Form Page 2): Include the primary site where the proposed supplement activities will be performed. If a portion of the proposed supplement activities will be performed at any other site(s), identify the locations in the fields provided.
• Sr/Key Personnel section (Form Page 2): List the PD/PI as the first person (regardless of their role on the supplement activities). List any other Senior/Key Personnel who are being added through this supplement, or for whom additional funds are being requested through this supplement; include a biographical sketch for each.
• Budget for Entire Proposed Project Period (Form Page 5): A proposed budget should be submitted using the PHS 398 budget forms and should only include funds requested for the additional supplement activities.
•     If applicable, attach documentation in the Appendix section indicating that the proposed research experience was approved by the Institutional Animal Care and Use Committee (IACUC) or human subjects Institutional Review Board (IRB) at the grantee institution. Adherence to the NIH policy for including women and minorities in clinical studies must also be ensured, if additional human subjects involvement is planned for the supplement component.

The grantee institution, on behalf of the PD/PI of the parent award, must submit the request for supplemental funds directly to the awarding component that supports the parent award. Submit a signed, typewritten original of the application, including the checklist, as a scanned pdf to:

Anil Wali, Ph.D.
NCI/Center to Reduce Cancer Health Disparities
Phone: 240-276-6183
E-mail: walia@mail.nih.gov
Liz Perruccio, Ph.D.
NCI/Center to Reduce Cancer Health Disparities
Phone: 240-276-6178
E-mail: liz.perruccio@nihg.gov

Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for Foreign institutions described throughout the Application Guide.

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.

Part I. Overview Information contains information about Key Dates and Times. Applicants are encouraged to submit electronic applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

For paper-based application submission, information on the process of receipt and determining if your application is considered on-time is described in detail in the PHS 398 Application Guide.

This initiative is not subject to intergovernmental review.

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

Applications must be submitted using the instructions specified above.

Applicants must complete all required registrations prior to submission. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission contact the Application Submission Contacts in Section VII.

Important reminders:
For applications submitted electronically on the SF424 (R&R) Application forms, all PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form of the SF 424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the (SAM). Additional information may be found in the Application Guide.

See more tips for avoiding common errors.

Not Applicable

Administrative Supplements do not receive peer review. Instead, the administrative criteria described below will be considered in the administrative evaluation process.

The staff of the NIH awarding component will evaluate requests for a supplement to determine its overall merit. The following general criteria will be used:

Budget and Period of Support

NIH staff will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

Overall Impact

Review and Selection Process

All applications will undergo review and evaluation for scientific and technical merit by a committee of NCI staff with expertise in the disciplines pertaining to this administrative supplement. Those applications judged to be responsive to the intent of this supplement will be evaluated based on the review criteria below and prioritized accordingly. Incomplete applications will not be reviewed. Late submissions will not be accepted.

The GMaP supplement applications should contain sufficient detail to allow assessment of the scientific merit of the proposed plans and the appropriateness of the request for supplemental funding in order to determine the relationship to the local (parent grant), regional (GMaP), and NCI research priorities.

Review criteria for the supplement will include the following:

Relevance: Are the proposed RCD-facilitated activities a reasonable extension of the research and outreach efforts of the parent grant?

Approach: Is the expertise and experiences of the proposed RCD appropriate to achieve the objectives of the supplement? Is the proposed plan for the RCD-facilitated career development and biospecimen/biobanking program appropriate to achieve the objectives of the supplement?

Quality: Is the proposed RCD-facilitated career development and biospecimen/biobanking program adequate to enhance workforce diversity, increase the number and use of biospecimen resources, and enhance CHD research?

Feasibility: Can the proposed RCD-facilitated career development and biospecimen/biobanking program be conducted with the resources and within the timeframe proposed?

Additionally, NIH staff will consider the ability of the proposed supplement activities to increase or preserve the parent award’s overall impact within the original scope of award:

• Will the administrative supplement increase or preserve the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved?
• Will the administrative supplement increase or preserve the likelihood for the program to exert a sustained, powerful influence on the research field(s) involved?

Post Award Requirements

Annual Progress Report: The PI must submit an annual Progress Report within their RPPR, which summarizes RCD activities, outcomes, and accomplishments per the Scope of Activities. Relevant instructions will be provided by NCI/CRCHD.

Final Cumulative Report: Within 90 days after the conclusion of the supplement period, the PI/PD must submit to the CRCHD Program Officials, in place of the annual progress report for that year, a Final Report summarizing RCD activities, outcomes, and accomplishments per the Scope of Activities.

In addition, each of the following criteria will be evaluated as applicable for the proposed supplement.

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, NIH staff will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, NIH staff will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

NIH staff will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

NIH staff will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Administrative supplement requests will undergo an administrative evaluation by NIH staff, but not a full peer review. Applications submitted for this funding opportunity will be assigned to the awarding component for the parent award and will be administratively evaluated using the criteria shown above.

Not Applicable

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. This may be as an NoA for the supplemental activities only; alternatively, it may be as either a revision to the current year NoA or included as part of a future year NoA. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website. When calculating the award for additional funds, NIH will 1) prorate funding if the requested budget period is adjusted at the time of award, and 2) use the institution’s current F&A rate; i.e., the rate in effect when the new funding is provided.

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

Any supplements to Cooperative Agreements will be subject to the same Cooperative Agreement terms and conditions as the parent award.

Reporting requirements will be specified in the terms and conditions of award as applicable to the supplemental activities. In most non-competing continuation applications, the progress report and budget for the supplement must be included with, but clearly delineated from, the progress report and budget for the parent award. The progress report must include information about the activities supported by the supplement even if support for future years is not requested. Continuation of support for the supplement activities in the remaining years of the competitive segment of the grant will depend upon satisfactory review by the NIH awarding component of progress for both the parent award and the supplement project, the research proposed for the next budget period, and the appropriateness of the proposed budget for the proposed effort. This information is submitted with the Research Performance Progress Report (RPPR) and financial statements as required in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period.  The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 Award Term and Conditions for Recipient Integrity and Performance Matters.

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

eRA Service Desk (Questions regarding ASSIST, eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Anil Wali, Ph.D.
NCI/Center to Reduce Cancer Health Disparities
Telephone: 240-276-6183
Email: walia@mail.nih.gov

Liz Perruccio, Ph.D.
NCI/Center to Reduce Cancer Health Disparities
Telephone: 240-276-6178
Email: liz.perruccio@nihg.gov

Not Applicable

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.